MX376118B - Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant. - Google Patents
Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant.Info
- Publication number
- MX376118B MX376118B MX2018015036A MX2018015036A MX376118B MX 376118 B MX376118 B MX 376118B MX 2018015036 A MX2018015036 A MX 2018015036A MX 2018015036 A MX2018015036 A MX 2018015036A MX 376118 B MX376118 B MX 376118B
- Authority
- MX
- Mexico
- Prior art keywords
- fosnetupitant
- physiologically balanced
- injectable formulations
- balanced injectable
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662345942P | 2016-06-06 | 2016-06-06 | |
| PCT/EP2017/063268 WO2017211663A1 (en) | 2016-06-06 | 2017-06-01 | Physiologically balanced injectable formulations of fosnetupitant |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018015036A MX2018015036A (es) | 2019-04-11 |
| MX376118B true MX376118B (es) | 2025-03-07 |
Family
ID=59055193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018015036A MX376118B (es) | 2016-06-06 | 2017-06-01 | Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant. |
Country Status (36)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11654154B2 (en) | 2019-01-29 | 2023-05-23 | Navinta Iii Inc | Process for preparing injectable Fosaprepitant Dimeglumine compositions having improved storage stability |
| US12097197B2 (en) | 2021-12-21 | 2024-09-24 | Slayback Pharma Llc | Stable liquid compositions of netupitant and palonosetron |
| JP7783403B2 (ja) * | 2022-03-23 | 2025-12-09 | 大鵬薬品工業株式会社 | ホスネツピタント又はその医薬上許容される塩の安定化製剤およびその製造方法 |
| WO2025036703A1 (en) * | 2023-08-13 | 2025-02-20 | Helsinn Healthcare Sa | Fosnetupitant for administration via intravenous bolus |
| WO2025056094A1 (zh) * | 2023-09-15 | 2025-03-20 | 广州帝奇医药技术有限公司 | 一种冻干制剂和注射液及其制备方法 |
| CN119185243A (zh) * | 2024-11-28 | 2024-12-27 | 山东齐都药业有限公司 | 福奈妥匹坦帕洛诺司琼口服掩味颗粒剂及其制备方法与应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL111960A (en) | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
| KR100286412B1 (ko) | 1993-12-29 | 2001-04-16 | 더블유. 지. 콜 | 치환된 모르폴린 유도체, 이의 제조방법 및 이를 포함하는 약제학적 조성물 |
| IL112778A0 (en) | 1994-03-04 | 1995-05-26 | Merck & Co Inc | Substituted heterocycles, their preparation and pharmaceutical compositions containing them |
| JO2735B1 (en) * | 2003-01-30 | 2013-09-15 | هيلسين هيلث كير أس ايه. | Liquid pharmaceutical formations of balloonosterone |
| US20060167072A1 (en) * | 2004-01-30 | 2006-07-27 | Helsinn Healthcare Sa | Liquid pharmaceutical formulations of palonosetron |
| US20100048607A1 (en) * | 2008-08-25 | 2010-02-25 | Chandrashekhar Kocherlakota | Formulations comprising palonosetron |
| US8426450B1 (en) | 2011-11-29 | 2013-04-23 | Helsinn Healthcare Sa | Substituted 4-phenyl pyridines having anti-emetic effect |
| EP2866797B1 (en) * | 2012-07-06 | 2020-04-29 | Pharmathen S.A. | Stable injectable pharmaceutical composition of neurokinin 1 receptor antagonist and process for preparation thereof |
-
2017
- 2017-06-01 SG SG11201809708PA patent/SG11201809708PA/en unknown
- 2017-06-01 EP EP17729822.1A patent/EP3435980B1/en active Active
- 2017-06-01 KR KR1020187034943A patent/KR102459416B1/ko active Active
- 2017-06-01 WO PCT/EP2017/063268 patent/WO2017211663A1/en not_active Ceased
- 2017-06-01 LT LTEP17729822.1T patent/LT3435980T/lt unknown
- 2017-06-01 BR BR112018074655-0A patent/BR112018074655B1/pt active IP Right Grant
- 2017-06-01 MA MA44513A patent/MA44513B1/fr unknown
- 2017-06-01 MD MDE20190164T patent/MD3435980T2/ro unknown
- 2017-06-01 MX MX2018015036A patent/MX376118B/es active IP Right Grant
- 2017-06-01 EA EA201892837A patent/EA036605B1/ru unknown
- 2017-06-01 PH PH1/2018/502524A patent/PH12018502524B1/en unknown
- 2017-06-01 CN CN201780034681.5A patent/CN109310627B/zh active Active
- 2017-06-01 AU AU2017276588A patent/AU2017276588B2/en active Active
- 2017-06-01 JP JP2018563684A patent/JP6936817B2/ja active Active
- 2017-06-01 EP EP19200383.8A patent/EP3626231A1/en not_active Withdrawn
- 2017-06-01 ES ES17729822T patent/ES2771226T3/es active Active
- 2017-06-01 SI SI201730178T patent/SI3435980T1/sl unknown
- 2017-06-01 PL PL17729822T patent/PL3435980T3/pl unknown
- 2017-06-01 HR HRP20200196TT patent/HRP20200196T1/hr unknown
- 2017-06-01 PT PT177298221T patent/PT3435980T/pt unknown
- 2017-06-01 RS RS20200100A patent/RS59852B1/sr unknown
- 2017-06-01 DK DK17729822.1T patent/DK3435980T3/da active
- 2017-06-01 MY MYPI2018001970A patent/MY194081A/en unknown
- 2017-06-01 CA CA3025837A patent/CA3025837C/en active Active
- 2017-06-01 UA UAA201812842A patent/UA122285C2/uk unknown
- 2017-06-01 PE PE2018003074A patent/PE20190347A1/es unknown
- 2017-06-02 US US15/611,785 patent/US10624911B2/en active Active
- 2017-06-02 AR ARP170101521A patent/AR108676A1/es unknown
- 2017-06-02 UY UY0001037273A patent/UY37273A/es active IP Right Grant
- 2017-06-06 TW TW106118613A patent/TWI725191B/zh active
- 2017-06-06 JO JOP/2017/0137A patent/JOP20170137B1/ar active
-
2018
- 2018-11-09 CO CONC2018/0011686A patent/CO2018011686A2/es unknown
- 2018-11-19 IL IL263126A patent/IL263126B/en active IP Right Grant
- 2018-11-22 CL CL2018003338A patent/CL2018003338A1/es unknown
- 2018-11-23 ZA ZA2018/07932A patent/ZA201807932B/en unknown
-
2019
- 2019-01-02 EC ECSENADI2019169A patent/ECSP19000169A/es unknown
-
2020
- 2020-02-10 CY CY20201100123T patent/CY1122755T1/el unknown
- 2020-03-13 US US16/817,683 patent/US11529362B2/en active Active
-
2021
- 2021-08-27 JP JP2021138576A patent/JP7223084B2/ja active Active
-
2022
- 2022-11-15 US US17/986,934 patent/US12208109B2/en active Active
-
2024
- 2024-12-23 US US18/999,533 patent/US20250235473A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP22023220A (es) | Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue | |
| MX376118B (es) | Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant. | |
| CO2017001994A2 (es) | Compuestos activos hacia bromodominios | |
| MX2016012574A (es) | Compuestos heteroarilo sustituidos y metodos de uso. | |
| MX2017016806A (es) | Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina. | |
| EA201792591A1 (ru) | Фармацевтические препараты | |
| MX2018011785A (es) | Derivados de indolina sustituidos como inhibidores de la replicacion viral del dengue. | |
| DOP2017000307A (es) | Formulación sólida oral que contiene irinotecán y método de preparación de la misma. | |
| EA201692043A1 (ru) | Лекарственная форма иммунодепрессанта | |
| CO2017012645A2 (es) | Agente antihipertensivo que comprende s-1-propenilcisteína o una sal del mismo como ingrediente activo | |
| MX387731B (es) | Composiciones farmacéuticas orales de mesalazina. | |
| PH12016502243A1 (en) | Pharmaceutical compositions for treating infectious diseases | |
| MX390899B (es) | Formulación de combinación de dosis fija, eflornitina y sulindaco. | |
| UA116499C2 (uk) | (r)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині | |
| MX385513B (es) | Composiciones farmaceuticas que comprenden safinamida. | |
| CY1122979T1 (el) | Φαρμακευτικη συνθεση για τη θεραπεια της μυκητιασης | |
| PH12018501991A1 (en) | Pharmaceutical composition for use in treating fibrosis | |
| CY1123966T1 (el) | Διαδικασια για την παρασκευη νατριουχου εποπροστενολης ενισχυμενης σταθεροτητας | |
| IN2013MU02015A (enExample) | ||
| AR104570A1 (es) | Métodos de tratamiento de una enfermedad neurodegenerativa | |
| BR112017024356A2 (pt) | clonidina e/ou derivados de clonidina para uso na prevenção de lesão na pele resultante de radioterapia | |
| UA112089C2 (uk) | Тверда лікарська форма комбінованого препарату седативної та снодійної дії, що містить доксиламін |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |